Document Detail

Drug mechanisms to help in managing resistant hypertension in obesity.
MedLine Citation:
PMID:  20532698     Owner:  NLM     Status:  MEDLINE    
Obesity is a major risk factor for the development of hypertension. Because the prevalence of obesity is increasing worldwide, the prevalence of obesity hypertension is also increasing. Importantly, hypertension in obesity is commonly complicated by dyslipidemia and type 2 diabetes mellitus and hence imposes a high cardiovascular disease risk. Furthermore, obesity is strongly associated with resistant hypertension. Activation of the sympathetic nervous system and the renin-angiotensin system, leading to renal sodium and water retention, links obesity with hypertension. There is also evidence for the release of factors by visceral adipose tissue promoting excessive aldosterone production, and a more central role of aldosterone in obesity hypertension is emerging. Randomized studies evaluating the effect of different classes of antihypertensive agents in obesity hypertension are scarce, short-lasting, and small. Considering the emerging role of aldosterone in the pathogenesis of obesity hypertension, mineralocorticoid receptor antagonism may play a more central role in the pharmacologic treatment of obesity hypertension in the near future.
Pieter M Jansen; Jan A H Danser; Wilko Spiering; Anton H van den Meiracker
Related Documents :
9709418 - Raised compartmental pressure in children: a basis for management.
10607938 - Autonomic cardiovascular regulation in obesity.
16330678 - Early socioeconomic position and blood pressure in childhood and adulthood: the cardiov...
1990758 - Gender differences in the systolic blood pressure response to exercise.
2323858 - Oxygen transport system before and after exposure to chronic hypoxia.
11083748 - Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hyperten...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current hypertension reports     Volume:  12     ISSN:  1534-3111     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-28     Completed Date:  2011-06-02     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  220-5     Citation Subset:  IM    
Division of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus MC, Room D432, 's Gravendijkwal 230, 3015CE, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects
Hypertension / drug therapy*,  etiology,  prevention & control
Life Style
Mineralocorticoid Receptor Antagonists
Obesity / complications,  drug therapy*
Receptors, Mineralocorticoid / drug effects
Renin-Angiotensin System / drug effects*
Risk Factors
Sympathetic Nervous System / drug effects*
Treatment Failure
Reg. No./Substance:
0/Antihypertensive Agents; 0/Mineralocorticoid Receptor Antagonists; 0/Receptors, Mineralocorticoid; 52-39-1/Aldosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Physical growth in children with reflux nephropathy with normal or mildly impaired renal function.
Next Document:  Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treat...